eVOLVE-HNSCCNCT06129864
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 18 versions: 18 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 8 words
- Study sites: 305 to 306
- Secondary endpoints: details revised at 9 of 13 entries
- Minor Study sites: 306 to 305v17
- Minor Site details revised at 8 of 306 sitesv16
- Notable Primary completion pushed from Apr 18, 2028 to Apr 17, 2030
- Study completion pushed from Sep 12, 2030 to Feb 28, 2031
- Study sites: 305 to 306
- Minor Site details revised at 15 of 305 sitesv14
Show 12 earlier versionsHide 12 earlier versions
- Minor Study sites: 304 to 305v13
- Minor Study sites: 300 to 304v12
- Minor Study sites: 295 to 300v11
- Minor Study sites: 294 to 295v10
- Minor Study sites: 291 to 294v9
- Minor Site details revised at 10 of 291 sitesv8
Notable Eligibility criteria shortened, about 35 wordsv7 Show 4 more changesShow less
- Study sites: 253 to 291
- Primary completion date: Jan 19, 2029 to Apr 18, 2028
- Study completion date: May 23, 2030 to Sep 12, 2030
- Secondary endpoints: details revised at 13 of 13 entries
- Minor Study sites: 209 to 253
- Study completion date: Jun 17, 2030 to May 23, 2030
- Minor Study sites: 195 to 209v5
- Minor Study sites: 192 to 195v4
- Minor Study sites: 161 to 192v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 72 to 161
- Start date changed from estimate of Nov 21, 2023 to Dec 14, 2023
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Progression-Free Survival (PFS) in participants with unresected LA-HNSCC with PD-L1 expressing tumors
Timeframe: Up to approximately 8 years
Secondary (13)
Progression-Free Survival (PFS) in the unresected LA-HNSCC intent-to-treat (ITT) population
Landmark Progression-Free Survival (PFS) Rates
Overall Survival (OS) in participants with unresected LA-HNSCC with PD-L1 expressing tumors
Landmark Overall Survival (OS) Rates
Overall Survival (OS) in the unresected LA-HNSCC ITT population
Show 8 moreShow less
Progression Free Survival 2 (PFS2)
Presence of Anti-Drug-Antibodies (ADAs) against volrustomig in serum
Participant-reported physical functioning
Participant-reported global health status (GHS)/quality of life (QoL)
Percentage of participants with Adverse Events
Area under the curve (AUC)
Maximum plasma concentration of the drug (Cmax)
The time taken to reach the maximum concentration (Tmax)
Arms and interventions
Study ArmExperimental
Participants in this arm will receive volrustomig.
Observation ArmNo intervention
Patients in this arm will undergo observation.
Drugs: volrustomig
Sites
306 sites in 23 countries
United States 70, China 40, Japan 26, Germany 14, India 14, Brazil 13, United Kingdom 12, Canada 11, Hungary 11, Poland 9, Spain 9, Thailand 9, France 8, Italy 8, Taiwan 8, Philippines 7, South Korea 7, Turkey (Türkiye) 7, Malaysia 6, Vietnam 6, Austria 5, Belgium 5, Puerto Rico 1